title: Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.
abstract: OBJECTIVE
  To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).
  
  
  RESULTS
  The mean anterior chamber flare was 10.7 ± 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 ± 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 ± 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).
  
  
  CONCLUSIONS
  No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD.
authors.affiliation: a Ordu University , Training and Research Hospital, Department of Ophthalmology , Ordu , Turkey.
authors.forename: Aslihan
authors.initials: A
authors.lastname: Uzun
authors.affiliation: b Ankara University, Faculty of Medicine , Department of Ophthalmology , Ankara , Turkey.
authors.forename: Fatime Nilufer
authors.initials: FN
authors.lastname: Yalcindag
authors.affiliation: b Ankara University, Faculty of Medicine , Department of Ophthalmology , Ankara , Turkey.
authors.forename: Sibel
authors.initials: S
authors.lastname: Demirel
authors.affiliation: b Ankara University, Faculty of Medicine , Department of Ophthalmology , Ankara , Turkey.
authors.forename: Figen
authors.initials: F
authors.lastname: Batýoðlu
authors.affiliation: b Ankara University, Faculty of Medicine , Department of Ophthalmology , Ankara , Turkey.
authors.forename: Emin
authors.initials: E
authors.lastname: Ozmert
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000378:metabolism*; D001082:Aqueous Humor / Q000378:metabolism*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Age-related macular degeneration; anterior chamber; aqueous flare; intravitreal injection; ranibizumab